Comment on: Ramos-Zavala et al. Effect of Diacerein on Insulin Secretion and Metabolic Control in Drug-Naïve Patients With Type 2 Diabetes: A Randomized Clinical Trial. Diabetes Care 2011;34:1591–1594 | Zendy

Natália Tobar | Zendy; Alexandre G. Oliveira | Zendy; Dioze Guadagnini | Zendy; Renata A. Bagarolli | Zendy; Guilherme Z. Rocha | Zendy; Tiago Gomes Araújo | Zendy; Patrícia O. Prada | Zendy; Mário J.A. Saad | Zendy

Open Access

Comment on: Ramos-Zavala et al. Effect of Diacerein on Insulin Secretion and Metabolic Control in Drug-Naïve Patients With Type 2 Diabetes: A Randomized Clinical Trial. Diabetes Care 2011;34:1591–1594

Author(s) -

Natália Tobar,

Alexandre G. Oliveira,

Dioze Guadagnini,

Renata A. Bagarolli,

Guilherme Z. Rocha,

Tiago Gomes Araújo,

Patrícia O. Prada,

Mário J.A. Saad

Publication year - 2012

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc11-1856

Subject(s) - medicine , diabetes mellitus , endocrinology , type 2 diabetes , insulin , drug , insulin resistance , pharmacology

Ramos-Zavala et al. (1) described in their report the effects of diacerein, an anti-inflammatory drug used in the treatment of rheumatic diseases, on insulin secretion in patients with type 2 diabetes. They showed that diacerein induced a significant decrease in fasting glucose levels, A1C levels, tumor necrosis factor-α levels, and interleukin (IL)-1β serum levels. By using the hyperinsulinemic-euglycemic clamp, they also showed that diacerein is able to improve insulin secretion but does not modify insulin sensitivity.Our laboratory recently investigated the antihyperglycemic effect of diacerein and the mechanisms responsible for …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research